[China BD 2024] FutureGen and AbbVie enters a 1.71 billion USD license on TL1A antibody FG-M701

Announced Date: 2024-06-13 ( June 13, 2024)

Asset Name: FG-M701

Licensor: FutureGen Biopharmaceutical (Beijing) (China)

Licensee (Buyer): AbbVie Inc.（US）

.

Asset Modality: fully human monoclonal antibody

Asset Target: TL1A

Potential Indication: treatment of inflammatory bowel disease (IBD)

Current Stage: Preclinical

.

Scope of Authority:

AbbVie will receive an exclusive global license to develop, manufacture and commercialize FG-M701. 

.

Payment Detail:

FutureGen will receive

$150 million in upfront and near-term milestone payments,

up to an additional $1.56 billion in clinical development, regulatory and commercial milestones,

tiered royalties up to low-double digits on net sales.

.

Link:

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease – Jun 13, 2024

Note:

Chinese Name of FutureGen Biopharmaceutical (Beijing)  明济生物制药（北京）